Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Контрацепция с фолатами и клиническая практика
Прилепская В.Н., Бостанджян Л.Л. Контрацепция с фолатами и клиническая практика. Гинекология. 2020; 22 (6): 101–107. DOI: 10.26442/20795696.2020.6.200585
________________________________________________
Prilepskaya V.N., Bostandzhian L.L. Folate contraception and clinical practice. Gynecology. 2020; 22 (6): 101–107. DOI: 10.26442/20795696.2020.6.200585
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Со времен «первой таблетки» произошла значительная эволюция гормональной контрацепции: появились низко- и микродозированные препараты, созданы препараты с компонентами, максимально приближенными к эндогенным гормонам, появились новые режимы дозирования и пути введения контрацептивов. Современные комбинированные оральные контрацептивы не только применяются для предотвращения нежелательной беременности, но и широко используются для лечения ряда гинекологических и негинекологических заболеваний. В последние годы разработаны два новых комбинированных оральных контрацептива с добавлением фолатов. Основная цель добавления фолатов в контрацептивы – профилактика пороков развития плода, которая обеспечивается повышением уровня фолатов в организме женщин репродуктивного возраста на фоне контрацепции и после ее отмены.
Ключевые слова: контрацепция, дроспиренон, фолаты, профилактика дефектов нервной трубки.
Ключевые слова: контрацепция, дроспиренон, фолаты, профилактика дефектов нервной трубки.
________________________________________________
Since the "first pill", there has been a significant evolution of hormonal contraception: low- and micro-dose drugs have appeared, drugs with components as close as possible to endogenous hormones have been developed, new dosage regimens and routes of contraceptive administration have been created. Modern combined oral contraceptives are not only used to prevent unwanted pregnancies, but are also widely used to treat a number of gynecological and non-gynecological diseases. In recent years, two new combined oral contraceptives with folate supplementation have been developed. The main purpose of adding folate to contraceptives is the prevention of fetal malformations, which is ensured by an increase in the level of folate in the body of women of reproductive age against the background of contraception and after its withdrawal.
Key words: contraception, drospirenone, folates, prevention of neural tube defects.
Полный текст
Список литературы
1. Rogers LM, Cordero AM, Pfeiffer C et al. Global folate status in women of reproductive age: a systematic review with emphasis on methodological issues. Ann N Y Acad Sci 2018; 1431 (1): 35–57.
2. Лиманова О.А., Торшин И.Ю., Сардарян И.С. и др. Обеспеченность микронутриентами и женское здоровье: интеллектуальный анализ клинико-эпидемиологических данных. Вопр. гинекологии, акушерства и перинатологии. 2014; 13 (2): 5–15.
[Limanova O.A., Torshin I.Yu., Sardaryan I.S. et al. Micronutrient provision and women’s health: intellectual analysis of clinicoepidemiological data. Gynecology, Obstetrics and Perinatology. 2014; 13 (2): 5–15 (in Russian).]
3. Макаров О.В., Керчелаева С.Б., Озолиня Л.А. Приобретенные и наследственные факторы тромбофилии в развитии осложнений беременности. М., 2006.
[Makarov O.V., Kerchelaeva S.B., Ozolinia L.A. Acquired and hereditary factors of thrombophilia in the development of pregnancy complications. Moscow, 2006 (in Russian).]
4. Мухин Н.А., Моисеев С.В., Фомин В.В. Гипергомоцистеинемия как фактор риска развития заболеваний сердечно-сосудистой системы. Клин. медицина. 2001; 6: 7–14.
[Mukhin N.A., Moiseev S.V., Fomin V.V. Gipergomotsisteinemiia kak faktor riska razvitiia zabolevaniĭ serdechno-sosudistoi sistemy. Klin. meditsina. 2001; 6: 7–14 (in Russian).]
5. Liu H, Huang GW, Zhang XM et al. Folic Acid supplementation stimulates notch signaling and cell proliferation in embryonic neural stem cells. J Clin Biochem Nutr 2010; 47 (2): 174–80.
6. Botto LD et al. N Engl J Med 1999; 341 (20): 1509–19.
7. Arya R et al. J Neonatol 2006; 20 (4): 316–26.
8. Brown J. Nutrition through the life cycle. 3rd ed. 2008.
9. Daly LE et al. JAMA 1995; 274: 1698–1702.
10. USPSTF. Ann Intern Med 2009;150 (9): 626–31.
11. EUROCAT. http://www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIA.pdf
12. Lamers Y et al. Am J Clin Nutr 2006; 84 (1): 156–61.
13. Cheschier N. Int J Gynaecol Obstet 2003; 83 (1): 123–33.
14. Джиландзе Н.М., Иванова Л.А. Использование биологически активных добавок студентами вузов. Медицина. Гигиена. Физиология. Биохимия. 2015; 1: 5–9.
[Dzhilandze N.M., Ivanova L.A. Ispol'zovanie biologicheski aktivnykh dobavok studentami vuzov. Meditsina. Gigiena. Fiziologiia. Biokhimiia. 2015; 1: 5–9 (in Russian).]
15. Bailey RL et al. Dietary supplement use in the Unites States, 2003–2006. J Nutr 2011; 141 (2): 261–6.
16. Centeno Tablante E, Pachón H, Guetterman HM, Finkelstein JL. Fortification of wheat and maize flour with folic acid for population health outcomes. Cochrane Database of Systematic Reviews 2019; 7: CD012150. DOI: 10.1002/14651858.CD012150.pub2
17. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами – новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 21–4.
[Prilepskaya V.N., Ivanova E.I., Bostandjan L.L. Contraceptives with folate – new possibilities for prophylaxis of fetal congenital abnormalities. Gynecology. 2013; 15 (1): 21–4 (in Russian).]
18. De-Regil LM et al. Cochrane Database Syst Rev 2010: CD007950.
19. MMWR Morb Mortal Wkly Rep 2004; 53 (17): 362–5.
20. Busby A et al. BMJ 2005; 330 (7491): 574–5.
21. Food & Drug Administration. http://www.fda.gov/ ohrms/dockets/ac/
03/minutes/ 4002M1_Final.pdf
22. Bart SS et al. Contraception 2012; 85: 42–50.
23. Прилепская В.Н., Назаренко Е.Г. Контрацепция и фолаты: новые возможности профилактики и лечения. Гинекология. 2018; 20 (1).
[Prilepskaya V.N., Nazarenko E.G. Contraception and folates: new opportunities for prevention and treatment. Gynecology. 2018; 20 (1) (in Russian).]
24. Монахов С.А. Фолатсодержащие антиандрогенные оральные контрацептивы: дерматологические аспекты. Гинекология. 2016; 18 (4): 57–8.
[Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 57–8 (in Russian).]
25. Монахов С.А., Иванов О.Л. Эстроген-гестагенные препараты в дерматологической практике (методическое пособие для врачей). М.: Чай Принт, 2014.
[Monakhov S.A., Ivanov O. L. Estrogen-progestational drugs in dermatological practice (methodological guide for doctors). Moscow: Chai Print, 2014 (in Russian).]
26. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol. Endocrinol 2007; 23 (3): 123–30.
27. Halbreich U, Borenstein J et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 (Suppl. 3): 1–23.
28. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72 (6): 414–21.
29. Pearlstein T, Yonkers KA, Fayyad R, Gillespie J. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord 2005; 85 (3): 275–82.
30. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
31. Halsted CH, Herbert V. Am J Clin Nutr 2003; 77 (4): 757–9.
32. Прилепская В.Н. Контрацепция с фолатами и реальная клиническая практика. Всероссийский научно-образовательный форум «Мать и дитя». Эффективная фармакотерапия. Акушерство и гинекология. 2018; 3–4.
[Prilepskaya V.N. Kontratseptsiia s folatami i real'naia klinicheskaia praktika. Vserossiiskii nauchno-obrazovatel'nyi forum “Mat' i ditia”. Effektivnaia farmakoterapiia. Akusherstvo i ginekologiia. 2018; 3–4 (in Russian).]
33. Osterhues A et al. Lancet 2009; 374 (9694): 959–61.
34. Ravin CR. AWHONN Lifelines 2004; 8 (1): 12–3.
35. De Jong-Van, den Berg LT et al. Am J Gynaecol Obstet 2005; 192 (1): 121−8.
36. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 111–2.
37. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 37–8.
38. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 112–3.
39. Cronin M et al. Obstet Gynecol 2009; 114 (3): 616–22.
40. Diefenbach K et al. Eur Contracept Reprod Health Care 2010; 15 (s1): 111–2.
41. Thomson Wadsworth: 109–110. Daly LE et al. JAMA 1995; 274:
1698–702.
42. De Batlle J et al. Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition. J Natl Cancer Inst 2014; 107 (1): 367.
43. Yang J et al. Interactions between serum folate and human papillomavirus with cervical intraepithelial neoplasia risk in a Chinese population-based study. Am J Clin Nutr 2018; 108 (5): 1034–42.
44. Faruk Abike et al. Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias. Arch Gynecol Obstet 2011; 284: 209–14.
45. Dietary reference intake for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington DC: National Academy Press, 1998.
46. Debowska R, Vincent C, Kruszewski M. The Repair Effect of Folacin Reducing Skin Damage Due to Radiotherapy 15th Congress of the European Academy of Dermatology and Venereology.
47. Yang YM, Zhang TT, Yuan L, Ren Y. The association between the C677T polymorphism in MTHFR gene and the risk of thyroid cancer: a meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18 (15): 2097–101.
48. Tio M, Andrici J, Cox MR, Eslick GD. Folate intake and the risk of upper gastrointestinal cancers: a systematic review and meta-analysis.
J Gastroenterol Hepatol 2014; 29 (2): 250–8.
49. Larsson SС, Giovannucci E, Wolk A et al. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006; 131 (4): 1271–81.
50. Tavani A, Malerba S, Pelucchi C et al. Dietary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
51. Тапильская Н.И. Контрацепция с фолатами и реальная клиническая практика. Всероссийский научно-образовательный форум «Мать и дитя». Эффективная фармакотерапия. Акушерство и гинекология. 2018; 3–4.
[Tapil'skaia N.I. Kontratseptsiia s folatami i real'naia klinicheskaia praktika. Vserossiiskii nauchno-obrazovatel'nyi forum “Mat' i ditia”. Effektivnaia farmakoterapiia. Akusherstvo i ginekologiia. 2018; 3–4 (in Russian).]
52. Малышкина А.И., Фетисова И.Н., Фетисов Н.С., Гордеева А.В. Роль фолатов в репродукции. Медицинский форум. https://www.umedp.ru/upload/iblock/e6a/e6a0a475db32ece27d7bba0185557a52.pdf
[Malyshkina A.I., Fetisova I.N., Fetisov N.S., Gordeeva A.V. Rol' folatov v reproduktsii. Meditsinskii forum. https://www.umedp.ru/upload/iblock/e6a/e6a0a475db32ece27d7bba0185557a52.pdf (in Russian).]
2. Лиманова О.А., Торшин И.Ю., Сардарян И.С. и др. Обеспеченность микронутриентами и женское здоровье: интеллектуальный анализ клинико-эпидемиологических данных. Вопр. гинекологии, акушерства и перинатологии. 2014; 13 (2): 5–15.
[Limanova O.A., Torshin I.Yu., Sardaryan I.S. et al. Micronutrient provision and women’s health: intellectual analysis of clinicoepidemiological data. Gynecology, Obstetrics and Perinatology. 2014; 13 (2): 5–15 (in Russian).]
3. Макаров О.В., Керчелаева С.Б., Озолиня Л.А. Приобретенные и наследственные факторы тромбофилии в развитии осложнений беременности. М., 2006.
[Makarov O.V., Kerchelaeva S.B., Ozolinia L.A. Acquired and hereditary factors of thrombophilia in the development of pregnancy complications. Moscow, 2006 (in Russian).]
4. Мухин Н.А., Моисеев С.В., Фомин В.В. Гипергомоцистеинемия как фактор риска развития заболеваний сердечно-сосудистой системы. Клин. медицина. 2001; 6: 7–14.
[Mukhin N.A., Moiseev S.V., Fomin V.V. Gipergomotsisteinemiia kak faktor riska razvitiia zabolevaniĭ serdechno-sosudistoi sistemy. Klin. meditsina. 2001; 6: 7–14 (in Russian).]
5. Liu H, Huang GW, Zhang XM et al. Folic Acid supplementation stimulates notch signaling and cell proliferation in embryonic neural stem cells. J Clin Biochem Nutr 2010; 47 (2): 174–80.
6. Botto LD et al. N Engl J Med 1999; 341 (20): 1509–19.
7. Arya R et al. J Neonatol 2006; 20 (4): 316–26.
8. Brown J. Nutrition through the life cycle. 3rd ed. 2008.
9. Daly LE et al. JAMA 1995; 274: 1698–1702.
10. USPSTF. Ann Intern Med 2009;150 (9): 626–31.
11. EUROCAT. http://www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIA.pdf
12. Lamers Y et al. Am J Clin Nutr 2006; 84 (1): 156–61.
13. Cheschier N. Int J Gynaecol Obstet 2003; 83 (1): 123–33.
14. Джиландзе Н.М., Иванова Л.А. Использование биологически активных добавок студентами вузов. Медицина. Гигиена. Физиология. Биохимия. 2015; 1: 5–9.
[Dzhilandze N.M., Ivanova L.A. Ispol'zovanie biologicheski aktivnykh dobavok studentami vuzov. Meditsina. Gigiena. Fiziologiia. Biokhimiia. 2015; 1: 5–9 (in Russian).]
15. Bailey RL et al. Dietary supplement use in the Unites States, 2003–2006. J Nutr 2011; 141 (2): 261–6.
16. Centeno Tablante E, Pachón H, Guetterman HM, Finkelstein JL. Fortification of wheat and maize flour with folic acid for population health outcomes. Cochrane Database of Systematic Reviews 2019; 7: CD012150. DOI: 10.1002/14651858.CD012150.pub2
17. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами – новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 21–4.
[Prilepskaya V.N., Ivanova E.I., Bostandjan L.L. Contraceptives with folate – new possibilities for prophylaxis of fetal congenital abnormalities. Gynecology. 2013; 15 (1): 21–4 (in Russian).]
18. De-Regil LM et al. Cochrane Database Syst Rev 2010: CD007950.
19. MMWR Morb Mortal Wkly Rep 2004; 53 (17): 362–5.
20. Busby A et al. BMJ 2005; 330 (7491): 574–5.
21. Food & Drug Administration. http://www.fda.gov/ ohrms/dockets/ac/
03/minutes/ 4002M1_Final.pdf
22. Bart SS et al. Contraception 2012; 85: 42–50.
23. Прилепская В.Н., Назаренко Е.Г. Контрацепция и фолаты: новые возможности профилактики и лечения. Гинекология. 2018; 20 (1).
[Prilepskaya V.N., Nazarenko E.G. Contraception and folates: new opportunities for prevention and treatment. Gynecology. 2018; 20 (1) (in Russian).]
24. Монахов С.А. Фолатсодержащие антиандрогенные оральные контрацептивы: дерматологические аспекты. Гинекология. 2016; 18 (4): 57–8.
[Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 57–8 (in Russian).]
25. Монахов С.А., Иванов О.Л. Эстроген-гестагенные препараты в дерматологической практике (методическое пособие для врачей). М.: Чай Принт, 2014.
[Monakhov S.A., Ivanov O. L. Estrogen-progestational drugs in dermatological practice (methodological guide for doctors). Moscow: Chai Print, 2014 (in Russian).]
26. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol. Endocrinol 2007; 23 (3): 123–30.
27. Halbreich U, Borenstein J et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 (Suppl. 3): 1–23.
28. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72 (6): 414–21.
29. Pearlstein T, Yonkers KA, Fayyad R, Gillespie J. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord 2005; 85 (3): 275–82.
30. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
31. Halsted CH, Herbert V. Am J Clin Nutr 2003; 77 (4): 757–9.
32. Прилепская В.Н. Контрацепция с фолатами и реальная клиническая практика. Всероссийский научно-образовательный форум «Мать и дитя». Эффективная фармакотерапия. Акушерство и гинекология. 2018; 3–4.
[Prilepskaya V.N. Kontratseptsiia s folatami i real'naia klinicheskaia praktika. Vserossiiskii nauchno-obrazovatel'nyi forum “Mat' i ditia”. Effektivnaia farmakoterapiia. Akusherstvo i ginekologiia. 2018; 3–4 (in Russian).]
33. Osterhues A et al. Lancet 2009; 374 (9694): 959–61.
34. Ravin CR. AWHONN Lifelines 2004; 8 (1): 12–3.
35. De Jong-Van, den Berg LT et al. Am J Gynaecol Obstet 2005; 192 (1): 121−8.
36. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 111–2.
37. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 37–8.
38. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 112–3.
39. Cronin M et al. Obstet Gynecol 2009; 114 (3): 616–22.
40. Diefenbach K et al. Eur Contracept Reprod Health Care 2010; 15 (s1): 111–2.
41. Thomson Wadsworth: 109–110. Daly LE et al. JAMA 1995; 274:
1698–702.
42. De Batlle J et al. Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition. J Natl Cancer Inst 2014; 107 (1): 367.
43. Yang J et al. Interactions between serum folate and human papillomavirus with cervical intraepithelial neoplasia risk in a Chinese population-based study. Am J Clin Nutr 2018; 108 (5): 1034–42.
44. Faruk Abike et al. Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias. Arch Gynecol Obstet 2011; 284: 209–14.
45. Dietary reference intake for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington DC: National Academy Press, 1998.
46. Debowska R, Vincent C, Kruszewski M. The Repair Effect of Folacin Reducing Skin Damage Due to Radiotherapy 15th Congress of the European Academy of Dermatology and Venereology.
47. Yang YM, Zhang TT, Yuan L, Ren Y. The association between the C677T polymorphism in MTHFR gene and the risk of thyroid cancer: a meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18 (15): 2097–101.
48. Tio M, Andrici J, Cox MR, Eslick GD. Folate intake and the risk of upper gastrointestinal cancers: a systematic review and meta-analysis.
J Gastroenterol Hepatol 2014; 29 (2): 250–8.
49. Larsson SС, Giovannucci E, Wolk A et al. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006; 131 (4): 1271–81.
50. Tavani A, Malerba S, Pelucchi C et al. Dietary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
51. Тапильская Н.И. Контрацепция с фолатами и реальная клиническая практика. Всероссийский научно-образовательный форум «Мать и дитя». Эффективная фармакотерапия. Акушерство и гинекология. 2018; 3–4.
[Tapil'skaia N.I. Kontratseptsiia s folatami i real'naia klinicheskaia praktika. Vserossiiskii nauchno-obrazovatel'nyi forum “Mat' i ditia”. Effektivnaia farmakoterapiia. Akusherstvo i ginekologiia. 2018; 3–4 (in Russian).]
52. Малышкина А.И., Фетисова И.Н., Фетисов Н.С., Гордеева А.В. Роль фолатов в репродукции. Медицинский форум. https://www.umedp.ru/upload/iblock/e6a/e6a0a475db32ece27d7bba0185557a52.pdf
[Malyshkina A.I., Fetisova I.N., Fetisov N.S., Gordeeva A.V. Rol' folatov v reproduktsii. Meditsinskii forum. https://www.umedp.ru/upload/iblock/e6a/e6a0a475db32ece27d7bba0185557a52.pdf (in Russian).]
________________________________________________
1. Rogers LM, Cordero AM, Pfeiffer C et al. Global folate status in women of reproductive age: a systematic review with emphasis on methodological issues. Ann N Y Acad Sci 2018; 1431 (1): 35–57.
2. Limanova O.A., Torshin I.Yu., Sardaryan I.S. et al. Micronutrient provision and women’s health: intellectual analysis of clinicoepidemiological data. Gynecology, Obstetrics and Perinatology. 2014; 13 (2): 5–15 (in Russian).
3. Makarov O.V., Kerchelaeva S.B., Ozolinia L.A. Acquired and hereditary factors of thrombophilia in the development of pregnancy complications. Moscow, 2006 (in Russian).
4. Mukhin N.A., Moiseev S.V., Fomin V.V. Gipergomotsisteinemiia kak faktor riska razvitiia zabolevaniĭ serdechno-sosudistoi sistemy. Klin. meditsina. 2001; 6: 7–14 (in Russian).
5. Liu H, Huang GW, Zhang XM et al. Folic Acid supplementation stimulates notch signaling and cell proliferation in embryonic neural stem cells. J Clin Biochem Nutr 2010; 47 (2): 174–80.
6. Botto LD et al. N Engl J Med 1999; 341 (20): 1509–19.
7. Arya R et al. J Neonatol 2006; 20 (4): 316–26.
8. Brown J. Nutrition through the life cycle. 3rd ed. 2008.
9. Daly LE et al. JAMA 1995; 274: 1698–1702.
10. USPSTF. Ann Intern Med 2009;150 (9): 626–31.
11. EUROCAT. http://www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIA.pdf
12. Lamers Y et al. Am J Clin Nutr 2006; 84 (1): 156–61.
13. Cheschier N. Int J Gynaecol Obstet 2003; 83 (1): 123–33.
14. Dzhilandze N.M., Ivanova L.A. Ispol'zovanie biologicheski aktivnykh dobavok studentami vuzov. Meditsina. Gigiena. Fiziologiia. Biokhimiia. 2015; 1: 5–9 (in Russian).
15. Bailey RL et al. Dietary supplement use in the Unites States, 2003–2006. J Nutr 2011; 141 (2): 261–6.
16. Centeno Tablante E, Pachón H, Guetterman HM, Finkelstein JL. Fortification of wheat and maize flour with folic acid for population health outcomes. Cochrane Database of Systematic Reviews 2019; 7: CD012150. DOI: 10.1002/14651858.CD012150.pub2
17. Prilepskaya V.N., Ivanova E.I., Bostandjan L.L. Contraceptives with folate – new possibilities for prophylaxis of fetal congenital abnormalities. Gynecology. 2013; 15 (1): 21–4 (in Russian).
18. De-Regil LM et al. Cochrane Database Syst Rev 2010: CD007950.
19. MMWR Morb Mortal Wkly Rep 2004; 53 (17): 362–5.
20. Busby A et al. BMJ 2005; 330 (7491): 574–5.
21. Food & Drug Administration. http://www.fda.gov/ ohrms/dockets/ac/
03/minutes/ 4002M1_Final.pdf
22. Bart SS et al. Contraception 2012; 85: 42–50.
23. Prilepskaya V.N., Nazarenko E.G. Contraception and folates: new opportunities for prevention and treatment. Gynecology. 2018; 20 (1) (in Russian).
24. Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 57–8 (in Russian).
25. Monakhov S.A., Ivanov O. L. Estrogen-progestational drugs in dermatological practice (methodological guide for doctors). Moscow: Chai Print, 2014 (in Russian).
26. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol. Endocrinol 2007; 23 (3): 123–30.
27. Halbreich U, Borenstein J et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 (Suppl. 3): 1–23.
28. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72 (6): 414–21.
29. Pearlstein T, Yonkers KA, Fayyad R, Gillespie J. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord 2005; 85 (3): 275–82.
30. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
31. Halsted CH, Herbert V. Am J Clin Nutr 2003; 77 (4): 757–9.
32. Prilepskaya V.N. Kontratseptsiia s folatami i real'naia klinicheskaia praktika. Vserossiiskii nauchno-obrazovatel'nyi forum “Mat' i ditia”. Effektivnaia farmakoterapiia. Akusherstvo i ginekologiia. 2018; 3–4 (in Russian).
33. Osterhues A et al. Lancet 2009; 374 (9694): 959–61.
34. Ravin CR. AWHONN Lifelines 2004; 8 (1): 12–3.
35. De Jong-Van, den Berg LT et al. Am J Gynaecol Obstet 2005; 192 (1): 121−8.
36. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 111–2.
37. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 37–8.
38. Von Stenglin A et al. Eur J Contracept Reprod Health Care 2010; 15 (s1): 112–3.
39. Cronin M et al. Obstet Gynecol 2009; 114 (3): 616–22.
40. Diefenbach K et al. Eur Contracept Reprod Health Care 2010; 15 (s1): 111–2.
41. Thomson Wadsworth: 109–110. Daly LE et al. JAMA 1995; 274:
1698–702.
42. De Batlle J et al. Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition. J Natl Cancer Inst 2014; 107 (1): 367.
43. Yang J et al. Interactions between serum folate and human papillomavirus with cervical intraepithelial neoplasia risk in a Chinese population-based study. Am J Clin Nutr 2018; 108 (5): 1034–42.
44. Faruk Abike et al. Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias. Arch Gynecol Obstet 2011; 284: 209–14.
45. Dietary reference intake for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington DC: National Academy Press, 1998.
46. Debowska R, Vincent C, Kruszewski M. The Repair Effect of Folacin Reducing Skin Damage Due to Radiotherapy 15th Congress of the European Academy of Dermatology and Venereology.
47. Yang YM, Zhang TT, Yuan L, Ren Y. The association between the C677T polymorphism in MTHFR gene and the risk of thyroid cancer: a meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18 (15): 2097–101.
48. Tio M, Andrici J, Cox MR, Eslick GD. Folate intake and the risk of upper gastrointestinal cancers: a systematic review and meta-analysis.
J Gastroenterol Hepatol 2014; 29 (2): 250–8.
49. Larsson SС, Giovannucci E, Wolk A et al. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006; 131 (4): 1271–81.
50. Tavani A, Malerba S, Pelucchi C et al. Dietary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
51. Tapil'skaia N.I. Kontratseptsiia s folatami i real'naia klinicheskaia praktika. Vserossiiskii nauchno-obrazovatel'nyi forum “Mat' i ditia”. Effektivnaia farmakoterapiia. Akusherstvo i ginekologiia. 2018; 3–4 (in Russian).
52. Malyshkina A.I., Fetisova I.N., Fetisov N.S., Gordeeva A.V. Rol' folatov v reproduktsii. Meditsinskii forum. https://www.umedp.ru/upload/iblock/e6a/e6a0a475db32ece27d7bba0185557a52.pdf (in Russian).
Авторы
В.Н. Прилепская*, Л.Л. Бостанджян
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*v_prilepskaya@oparina4.ru
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*v_prilepskaya@oparina4.ru
________________________________________________
Vera N. Prilepskaya*, Lana L. Bostandzhian
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*v_prilepskaya@oparina4.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.